Skip to main content

Advertisement

Log in

Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The main objective of the present study was to estimate the levels of soluble CD44 in cervical cancer patients by determining whether it consistently discriminates the carcinoma of the cervix from early or premalignant stage of the cervical cancer. Serum concentrations of sCD44s in cervical cancer patients were determined by an enzyme-linked immunosorbent assay from serum of 50 cases of cervical cancer patients and 50 cases of suspected patients with premalignant disease of cervical intraepithelial neoplasia. The sensitivity and specificity of the test for differentiating carcinoma of the cervix from premalignant stage were evaluated by plotting receiver operating characteristic (ROC) curve. Significant increase in the levels of soluble CD44 was observed in cervical cancer patients (664.80 ± 26.58 ng/ml), when compared to healthy (P < 0.001) and suspected (P < 0.05) or premalignant cases (275.19 ± 24.39 and 514.33 ± 54.57 ng/ml, respectively). High-grade squamous intraepithelial lesions, adenocarcinoma in situ and premalignance with dysplasia show significant (P < 0.001) increase in the concentration of soluble CD44 levels when compared to other types. A ROC curve was plotted and estimated the threshold value as 633.11 ng/ml. In conclusion, the data indicated an up-regulation of soluble CD44 protein which detect and differentiates the cervical carcinoma from premalignant cases with 62.6 % sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Garnett GP, Kim JJ, French K, Goldie SJ. Modeling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24:S178–86.

    Article  Google Scholar 

  2. Zheng GX, Wang CX, Qu X, Den XM, Deng BP, Zhang J. Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol. 2006;28(4):282–7.

    PubMed  CAS  Google Scholar 

  3. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.

    Article  PubMed  CAS  Google Scholar 

  4. Givehchian M, Woerner SM, Lacroix J, Zöller M, Drings P, Becker H, et al. Expression of CD44 splice variants in normal respiratory epithelium and 11 bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene. 1996;12:1137–44.

    PubMed  CAS  Google Scholar 

  5. Higashikawa K, Yokozaki H, Ue T, Taniyama K, Ishikawa T, Tarin D, Tahara E. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer. 1996;66:11–7.

    Article  PubMed  CAS  Google Scholar 

  6. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica S, Grossi CE. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11:134–41.

    Article  PubMed  Google Scholar 

  7. Ermak G, Jennings T, Robinson L, Ross JS, Figge J. Restricted patterns of CD44 variant expression in human papillary thyroid carcinoma. Cancer Res. 1996;56:1037–42.

    PubMed  CAS  Google Scholar 

  8. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer. 1995;72:1494–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Jalknen S, Joensuu H, Soderstroom KO, Klemi P. Lymphocyte homing and clinical behavior of non-Hodgkin’s lymphoma. J clin Invest. 1991;87:1835–40.

    Article  Google Scholar 

  10. Terpe HJ, Stark H, Prehm P, Gunthert U. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry. 1994;101:79–89.

    Article  PubMed  CAS  Google Scholar 

  11. Miyake K, Underhill CB, Lesley J, Kincade PW. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyluronate recognistion. J Exp Med. 1990;172:69–75.

    Article  PubMed  CAS  Google Scholar 

  12. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at 12 alternatively spliced exons. Proc Natl Acad Sci. 1992;89:12160–4.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  14. Mulder JWR, Kruyt PM, Sewnath M, Seldernrijk CA, Weidema WF, Offerhaus GJA, Pals ST. Colorectal Cancer prognosis and expression of exon v6-containing CD44 proteins. Lancet. 1994;344:1470–2.

    Article  PubMed  CAS  Google Scholar 

  15. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422–6.

    PubMed  CAS  Google Scholar 

  16. Sinn HP, Heider KH, Skroch-Angel P, von Minckwitz G, Kaufmann M, Herrlich P, Ponta H. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat. 1995;36:307–13.

    Article  PubMed  CAS  Google Scholar 

  17. Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene. 2003;22:8716–22.

    Article  PubMed  CAS  Google Scholar 

  18. Vishnu Vardhan R, Sarma KVS. Determining the optimal cut of point in an ROC curve: a spreadsheet approach. Inter J Stat Analysis. 2012;2(3):219–25.

    Google Scholar 

  19. Kainz C, Kohlberger P, Sliutz G. Splice variants of cd44 in human cervical cancer stage Ib to IIb. Gynecol Oncol. 1995;57:383–7.

    Article  PubMed  CAS  Google Scholar 

  20. Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G. Prognostic value of CD44 splice variants in human cervical cancer stage III. Eur J Cancer. 1995;31:1706–9.

    Article  Google Scholar 

  21. Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer. 1995;60:471–7.

    Article  PubMed  CAS  Google Scholar 

  22. Ioachim E, Assimakopoulos D, Goussia AC, Peschos D, Skevas A, Agnantis NJ. Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: an immunohistochemical study including correlation with Rb, p53, Ki-67 and PCNA. Histol Histopathol. 1999;14(4):1113–8.

    PubMed  CAS  Google Scholar 

  23. Nanda K, McCrory DC, Myers ER. Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematicic review. Ann Intern Med. 2000;132:810–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The first author extends his thanks to UGC-Non-SAP (BSR), New Delhi fellowship for giving financial assistance and also thanks to Prof. Raju Naidu, Department of Radiation Oncology, Government General Hospital, Guntur, Andhra Pradesh, for providing pre- and posttreated cervical cancer samples.

Conflict of interest

The authors declare that there is no conflict of interests regarding the publication of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lokanatha Valluru.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dasari, S., Rajendra, W. & Valluru, L. Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. Med Oncol 31, 139 (2014). https://doi.org/10.1007/s12032-014-0139-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0139-9

Keywords

Navigation